◎ Sugi Atlas

Atlas / Drug / Tetanus Toxoid

Tetanus Toxoid

drug
On this page

Also known as Equilis teTetanus toxoid component of hexacimaTetanus toxoid component of hexavacTetanus toxoid component of hexyonTetanus toxoid component of primavaxTetanus toxoid component of quintanrixTetanus toxoid component of triacelluvaxTetanus toxoid component of vaxelis

Summary

Tetanus Toxoid (CHEMBL2108875) is an approved vaccine component (ATC J07AM51); indicated across 26 conditions including tetanus and pneumonia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Vaccine component
  • ATC class: J07AM51 (+2 more)
  • Indications: 26 conditions
  • Clinical trials: 18

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108875
NameTetanus Toxoid
TypeVaccine component
Max phase4
ATCJ07AM51, J07AM01, J07AM52

Also known as: Equilis te, Tetanus toxoid, Tetanus toxoid component of hexacima, Tetanus toxoid component of hexavac, Tetanus toxoid component of hexyon, Tetanus toxoid component of primavax, Tetanus toxoid component of quintanrix, Tetanus toxoid component of triacelluvax, Tetanus toxoid component of vaxelis, TETANUS TOXOID

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

26 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
tetanus4MONDO:0005526EFO:0005593
pneumonia3MONDO:0005249EFO:0003106
Dengue hemorrhagic fever3MONDO:0005358EFO:0004227
meningococcal infection3MONDO:0005373EFO:0004249
meningococcal meningitis3MONDO:0018059EFO:1001040
multiple sclerosis3MONDO:0005301MONDO:0005301
dengue disease3MONDO:0005502EFO:0005547
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
HIV infectious disease2MONDO:0005109EFO:0000764
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
rheumatoid arthritis2MONDO:0008383EFO:0000685
plasma cell myeloma2MONDO:0009693EFO:0001378
astrocytoma (excluding glioblastoma)2MONDO:0019781EFO:0000272
oligodendroglioma2MONDO:0016695EFO:0000632
peritoneal neoplasm2MONDO:0006901MONDO:0002087
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
ovarian cancer2MONDO:0008170MONDO:0008170
paraganglioma2MONDO:0000448EFO:1000453
colorectal neoplasm2MONDO:0005335MONDO:0005575
neoplasm1MONDO:0005070EFO:0000616
cutaneous melanoma1MONDO:0005012EFO:0000389
head and neck cancer1MONDO:0005627EFO:0006859
typhoid fever1MONDO:0005619EFO:0006789
Alzheimer disease1MONDO:0004975MONDO:0004975

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

PhaseTrials
Not specified5
PHASE24
PHASE43
PHASE32
PHASE1/PHASE22
PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03180034PHASE4ACTIVE_NOT_RECRUITINGComparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
NCT05237947PHASE4ACTIVE_NOT_RECRUITINGSingle-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial
NCT02570347PHASE4TERMINATEDRoutine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite
NCT02628886PHASE3UNKNOWNProtecting From Pneumococcus in Early Life (The PROPEL Trial)
NCT04429295PHASE3COMPLETEDStudy of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand
NCT06639074PHASE2RECRUITINGFolate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
NCT06939777PHASE1/PHASE2NOT_YET_RECRUITINGSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
NCT00027833PHASE2UNKNOWNVaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
NCT01187433PHASE2COMPLETEDStudy of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
NCT02518555PHASE2COMPLETEDIbrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06302374PHASE1/PHASE2COMPLETEDSafety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults
NCT00369291PHASE1TERMINATEDCpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
NCT00639639PHASE1COMPLETEDVaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00000105Not specifiedTERMINATEDVaccination With Tetanus and KLH to Assess Immune Responses.
NCT00004735Not specifiedCOMPLETEDThe Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV
NCT00258882Not specifiedCOMPLETEDDescriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
NCT03535779Not specifiedCOMPLETEDCharacterisation of Human B Cell Maturation in Response to Vaccination
NCT06130462Not specifiedCOMPLETEDDetection of Aluminium-reactive T-lymphocytes in Patients With Vaccination Granulomas

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 14

This page pulls from 14 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem